{"id":"efgartigimod-iv-or-efgartigimod-ph20-sc","safety":{"commonSideEffects":[{"rate":"10%","effect":"Injection site reaction"},{"rate":"20%","effect":"Headache"},{"rate":"15%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Efgartigimod is a human IgG1 antibody that targets and depletes muscle relaxant proteins, including muscle-specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4).","oneSentence":"Monoclonal antibody targeting muscle relaxant proteins","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:59:24.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myasthenia Gravis"}]},"trialDetails":[{"nctId":"NCT06299748","phase":"","title":"A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.","status":"RECRUITING","sponsor":"argenx","startDate":"2023-11-30","conditions":"Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":279},{"nctId":"NCT05374590","phase":"PHASE2, PHASE3","title":"Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis","status":"ENROLLING_BY_INVITATION","sponsor":"argenx","startDate":"2022-08-18","conditions":"Generalized Myasthenia Gravis, gMG","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Efgartigimod IV or Efgartigimod PH20 SC","genericName":"Efgartigimod IV or Efgartigimod PH20 SC","companyName":"argenx","companyId":"argenx","modality":"Biologic","firstApprovalDate":"","aiSummary":"Monoclonal antibody targeting muscle relaxant proteins Used for Myasthenia Gravis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}